Fig. 1: MCM2 is high expressed in HCC tissues and is associated with poor prognosis. | Cell Death Discovery

Fig. 1: MCM2 is high expressed in HCC tissues and is associated with poor prognosis.

From: MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling

Fig. 1

a–d Expression of MCM2 at the transcription level between HCC and normal liver tissues in TCGA LIHC dataset, GSE14520 dataset, GXMU cohort and GSE76427, and differences of MCM2 expression were statistically significant in each cohort; e Expression of MCM2 in HCC, para-carcinoma and normal liver tissues in GXMU cohort determined by immunohistochemistry assay, and the intensity of MCM2 expression was significantly higher in HCC than in para-carcinoma and liver tissue; f The expression of MCM2 in HCC patients with different BCLC stages in TCGA LIHC dataset, and patients in advanced BCLC stage were with higher expression of MCM2; g The immunoblotting for MCM2 expression of HCC tissues (T) and normal liver tissues (N) in GXMU cohort, determined by Western Blot assay; h–j Using the median MCM2 as the cut-off value, the prognosis of patients with high and low expression HCC differed significantly, with a poor prognosis for those with high MCM2.

Back to article page